+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors



Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors



American Journal of Obstetrics & Gynecology 172(2 PART 1): 574-579



OBJECTIVE: Our purpose was to evaluate the efficacy and toxicity of single-agent methotrexate chemotherapy and to identify factors associated with chemotherapy resistance in patients with nonmetastatic gestational trophoblastic tumors. STUDY DESIGN: A total of 337 patients with nonmetastatic gestational trophoblastic tumors (choriocarcinoma and invasive mole) received treatment at the Brewer Trophoblastic Disease Center of Northwestern University Medical School from 1962 through 1990. Of the 337 patients, 253 (75.0%) were treated initially with single-agent methotrexate 0.4 mg/kg intravenously daily for 5 days per treatment course repeated every 14 days. RESULTS: All 337 patients with nonmetastatic gestational trophoblastic tumors were cured. Of the 253 patients initially treated with methotrexate, resistance developed in 27 (10.7%), 22 (8.7%) required a second agent (actinomycin D), 3 (1.2%) required multiagent chemotherapy, and 2 (0.8%) had a hysterectomy to achieve complete remission. Factors associated with the development of resistance were pretreatment human chorionic gonadotropin level gtoreq 50,000 mIU/ml (36%, p lt 0.001), nonmolar antecedent pregnancy (26%, p lt 0.02), and clinicopathologic diagnosis of choriocarcinoma (20.5%, p = 0.02). Significant methotrexate toxicity requiring a change to a second agent occurred in only 12 patients (4.7%), the most common side effect being severe stomatitis. CONCLUSIONS: In a large series of patients with nonmetastatic gestational trophoblastic disease, single-agent methotrexate chemotherapy proved to be an extremely well-tolerated and effective treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 009421313

Download citation: RISBibTeXText

PMID: 7856688

DOI: 10.1016/0002-9378(95)90575-8


Related references

Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Gynecologic Oncology 52(1): 114-115, 1994

What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. Gynecologic Oncology 102(1): 103-110, 2006

Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecologic Oncology 125(3): 572-575, 2012

Single agent weekly methotrexate mtx therapy in the treatment of nonmetastatic gestational trophoblastic disease nmgtd. Gynecologic Oncology 26(3): 414, 1987

Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. Journal of Clinical Oncology 14(10): 2769-2773, 1996

Single-agent chemotherapy for nonmetastatic gestational trophoblastic neoplasia. Perspectives for the 21st century after three decades of use. Journal of Reproductive Medicine 36(1): 49-55, 1991

Treatment results of methotrexate and folinic acid as primary chemotherapy for nonmetastatic gestational trophoblastic neoplasia. Journal of the Medical Association of Thailand 88(7): 886-890, 2005

Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. American Journal of Obstetrics & Gynecology 174(6): 1917-1924, 1996

Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate--folinic acid. American Journal of Obstetrics and Gynecology 144(1): 88-92, 1982

Methotrexate infusion and folinic acid in the primary therapy of nonmetastatic gestational trophoblastic tumors. Gynecologic Oncology 36(1): 56-59, 1990

Curative effects and influenced factors of primary chemotherapy with single-agent methotrexate on low-risk gestational trophoblastic neoplasia. Zhonghua Yi Xue Za Zhi 97(23): 1769-1772, 2018

Failure of single dose methotrexate followed by citrovorum factor in nonmetastatic gestational trophoblastic neoplasia. Gynecologic Oncology 37(3): 412-416, 1990

A single institution experience with weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Gynecologic Oncology 60(2): 292-294, 1996

Treatment of nonmetastatic gestational trophoblastic disease with oral methotrexate. American Journal of Obstetrics & Gynecology 157(5): 1166-1168, 1987

Single-agent therapy for nonmetastatic and low-risk gestational trophoblastic disease. Journal of Reproductive Medicine 43(1): 69-74, 1998